Drugs / 177Lu-FC516
last change Apr 2026 re-read 3 minutes ago

177Lu-FC516

Developed for
prostate cancer
Investigated by
Affiliated Hospital of Jiangnan University · FindCure Biosciences (ZhongShan) Co., Ltd.

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 0 NCT07542379 Apr 2026 → May 2027 expected prostate cancer FindCure Biosciences (ZhongShan) Co., Ltd. Not yet recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as 177Lu-FC516 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07542379 ↗